Onkos Surgical, Inc. a leader in the field of musculoskeletal oncology and personalized orthopaedics announced today a multi-year agreement with Integrum AB (INTEG B: Nasdaq First North exchange). The collaboration between companies will commence immediately and will be focused on expanding the US market for Integrum’s OPRA (Osseoanchored Prostheses for the Rehabilitation of Amputees) Implant System; a revolutionary osseoinstegrated bone-anchored prosthetic technology.
Patrick Treacy, co-founder and CEO stated, “We are delighted to partner with Dr. Brånemark and Integrum, global experts and leading pioneers in the field of osseointegration. Integrum continues to revolutionize the field of bone anchored prosthetics and, given our focus in limb salvage, the OPRA™ technology is complementary to our portfolio strategy. The combined expertise of both companies will provide surgeons with greater access to advanced bone anchored prosthetics and provide patients with meaningful reconstructive options.”
The OPRA™ Implant System is the only FDA-approved, bone-anchored prosthetic solution available in the United States. OPRA™ consists of an anchorage element (fixture) and a skin penetrating device (abutment). The fixture is surgically inserted into the femur and after a healing time of several months the abutment is connected to the fixture. The prosthetic leg is then attached directly to the abutment via the OPRA™ Axor™, a prosthetic connection and safety device.